[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652618":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":11,"locations":17,"responsibleParty":32,"collaborators":10,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":39,"acronym":10,"eligibilityCriteria":40,"healthyVolunteers":37,"sex":41,"minAge":42,"maxAge":43,"enrollmentInfo":44,"targetDuration":47,"studyType":48,"phases":10,"briefSummary":49,"conditions":50,"keywords":10,"overallStatus":53,"whyStopped":10,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"Tenapanor",null,[12],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},"Li Zuo","CONTACT","+86-13910028495","zuoli@bjmu.edu.cn",[18],{"facility":5,"status":10,"city":19,"state":20,"zip":21,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"Beijing","Beijing Municipality","100000","China","CN",{"type":25,"coordinates":26},"Point",[27,28],116.39723,39.9075,{"lat":28,"lon":27},[31],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},{"type":33,"investigatorFullName":13,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Director, Department of Nephrology, Peking University People's Hospital; Chief Physician, Professor","100652618","real-world-efficacy-and-safety-of-tenapanor-plus-phosphate-binders-in-hemodialysis-patients-with-hyperphosphatemia-100652618",false,"NCT07776119","Real-World Efficacy and Safety of Tenapanor Plus Phosphate Binders in Hemodialysis Patients With Hyperphosphatemia","Inclusion Criteria:\n\n1. The subject has provided written informed consent prior to the initiation of any study-related activities.\n2. Male or female subjects aged ≥18 years at the time of signing the informed consent form.\n3. The subject is receiving regular maintenance hemodialysis (3 times per week, 4 hours per session) for at least 3 months.\n4. The patient has been on phosphate binder therapy for at least 3 weeks, with a stable dose.\n5. Serum phosphorus \\> 4.5 mg\u002FdL.\n\nExclusion Criteria:\n\n1. Hypersensitivity to Tenapanor or any excipients of the formulation.\n2. History of diarrhea within 1 week prior to the start of treatment. Diarrhea is defined as a Bristol Stool Form Scale (BSFS) score ≥6 (i.e., mushy or liquid stools with no solid pieces), a daily bowel movement frequency ≥3 times, and a duration of ≥2 days.\n3. Life expectancy \\\u003C 6 months.\n4. Expected or planned kidney transplantation during the study period.\n5. History of inflammatory bowel disease (IBD) or irritable bowel syndrome with diarrhea (IBS-D).\n6. Any other condition that, in the opinion of the Investigator, makes the patient unsuitable for enrollment.","ALL","18 Years","100 Years",{"count":45,"type":46},200,"ESTIMATED","6 Months","OBSERVATIONAL","The efficacy and safety of tenapanor plus PBs in Chinese patients are still unclear. Therefore, we aim to conduct a real-world study to explore the effect of combining two drugs with different mechanisms on hyperphosphatemia management.This real-world study will enroll hemodialysis patients with hyperphosphatemia who are on PBs therapy.",[51,52],"CKD 5D, Hemodialysis","Hyperphosphatemia Undergoing Hemodialysis","NOT_YET_RECRUITING","2026-08-17",{"date":56,"type":57},"2026-08-20","ACTUAL",{"date":56,"type":46},{"date":60,"type":46},"2027-10-10",{"name":5,"class":6},1]